Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes?
Platelets play a key role in hemostasis but are also responsible for the formation of pathogenic thrombi underlying the acute clinical manifestations of vascular atherothrombotic disease. Platelets are activated by multiple pathways, including adenosine diphosphate (ADP), thromboxane A(2) (TXA(2)), and thrombin, ultimately leading to formation of platelet-rich thrombi that occlude the arterial lumen, resulting in ischemia and cardiovascular events. Current oral antiplatelet agents inhibit the TXA(2) (aspirin [ASA]) and ADP platelet activation pathways (P2Y(12) ADP receptor antagonists) and have demonstrated clinical efficacy for the reduction of morbidity and mortality in patients with atherothrombotic disease. However, these agents are associated with residual risk for thrombotic events, bleeding risk, and variability in response. Thus, there is a strong clinical need for novel antiplatelet therapies that decrease the risk of thrombotic events without exposing patients to increased risk of bleeding. This review describes the clinical safety and efficacy of ASA and P2Y(12) ADP receptor antagonists, the limitations of current antiplatelet therapy, and novel therapies in development, including newer P2Y(12) ADP receptor antagonists and protease-activated receptor (PAR-1) inhibitors.
Moser
Martin
M
Internal Medicine III, University Hospital Freiburg, Hugstetter Str 55, 79106, Freiburg, Germany. Martin.Moser@uniklinik-freiburg.de
Bode
Christoph
C
D000284:Administration, Oral; D001777:Blood Coagulation / Q000187:drug effects*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors
J Am Coll Cardiol. 2007 Oct 16;50(16):1541-7
17936152
Circulation. 2003 Oct 7;108(14):1682-7
14504182
Am J Med. 2007 Jul;120(7):631-5
17602938
N Engl J Med. 2005 Mar 24;352(12):1179-89
15758000
BMJ. 2002 Jan 12;324(7329):71-86
11786451
Circulation. 2008 Oct 14;118(16):1626-36
18757948
Curr Med Chem Cardiovasc Hematol Agents. 2003 Mar;1(1):37-45
15317289
Lancet. 2001 Aug 18;358(9281):527-33
11520521
Lancet. 2008 Apr 19;371(9621):1353-63
18377975
J Pharmacol Exp Ther. 2003 Feb;304(2):855-61
12538843
J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16
17418288
Platelets. 2001 Jun;12(4):197-209
11454254
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
Circ Res. 2006 Dec 8;99(12):1293-304
17158345
Lancet. 2009 Feb 28;373(9665):723-31
19249633
J Med Chem. 2008 Jun 12;51(11):3061-4
18447380
Am Heart J. 2009 Sep;158(3):335-341.e3
19699854
N Engl J Med. 2009 Dec 10;361(24):2318-29
19915221
N Engl J Med. 2009 Jan 22;360(4):363-75
19106083
N Engl J Med. 2008 Aug 28;359(9):938-49
18753650
N Engl J Med. 2006 Apr 20;354(16):1706-17
16531616
Am J Cardiol. 2005 Apr 15;95(8):973-5
15820166
Am J Cardiol. 2003 Oct 15;92(8):930-5
14556868
J Thromb Haemost. 2005 Aug;3(8):1800-14
16102047
Thromb Haemost. 2009 Jul;102(1):7-14
19572061
N Engl J Med. 2009 Sep 10;361(11):1045-57
19717846
J Atheroscler Thromb. 2010 Feb 26;17(2):156-64
20124733
Am Heart J. 2005 Oct;150(4):690-4
16209967
Mt Sinai J Med. 2006 Jan;73(1):431-9
16470323
J Am Coll Cardiol. 2007 May 15;49(19):1982-8
17498584
N Engl J Med. 1988 Jun 30;318(26):1714-9
2967433
Lancet. 2009 Jan 24;373(9660):309-17
19108880
Eur Heart J. 2008 Jan;29(1):21-30
18055486
J Am Coll Cardiol. 2006 Oct 3;48(7):1339-45
17010792
Circulation. 2007 Dec 11;116(24):2793-801
18025530
Neurology. 2008 Aug 26;71(9):650-5
18685137
J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50
17084243
Lancet. 1996 Nov 16;348(9038):1329-39
8918275
N Engl J Med. 2009 Jan 22;360(4):354-62
19106084
Circulation. 2006 Aug 22;114(8):774-82
16908769
JAMA. 2004 Oct 20;292(15):1875-82
15494586
N Engl J Med. 2009 Dec 10;361(24):2330-41
19915222
N Engl J Med. 2007 Dec 13;357(24):2482-94
18077812
Circ Res. 2007 May 11;100(9):1261-75
17495233
Circulation. 2004 Jun 29;109(25):3171-5
15184279
Eur Heart J. 2003 Oct;24(20):1815-23
14563340
N Engl J Med. 2007 Nov 15;357(20):2001-15
17982182
Lancet. 2009 Mar 14;373(9667):919-28
19286091
Thromb Haemost. 2009 Aug;102(2):248-57
19652875
Nat Clin Pract Cardiovasc Med. 2008 Dec;5(12):766-80
18957959
Eur J Pharmacol. 2003 Jul 25;473(2-3):163-9
12892834
Thromb Haemost. 2009 Jul;102(1):111-9
19572075
JAMA. 2002 Nov 20;288(19):2411-20
12435254
Thromb Haemost. 2004 Aug;92(2):311-6
15269827
Circulation. 2009 Oct 20;120(16):1569-76
19805650
Eur Heart J. 2006 May;27(9):1038-47
16476694
Catheter Cardiovasc Interv. 2003 May;59(1):21-5
12720236
N Engl J Med. 1983 Aug 18;309(7):396-403
6135989
Eur Heart J. 2009 Mar;30(6):655-61
18713759
Eur Heart J. 2006 May;27(10):1166-73
16621870
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):403-12
18174460
Cardiovasc Drugs Ther. 2009 Dec;23(6):489-99
19890703
Lancet. 2009 May 30;373(9678):1849-60
19482214
Am Heart J. 2009 Dec;158(6):998-1004.e1
19958867
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):288-92
17190826
Am Heart J. 2009 Sep;158(3):327-334.e4
19699853
Lancet. 2005 Nov 5;366(9497):1607-21
16271642
Circulation. 2009 Apr 14;119(14):1873-82
19332461
BMJ. 2008 Jan 26;336(7637):195-8
18202034
Chest. 2003 Sep;124(3 Suppl):18S-25S
12970120
JAMA. 2004 Oct 6;292(13):1555-62
15467057
J Invasive Cardiol. 2004 Apr;16(4):169-74
15152138
Am J Cardiol. 2005 Nov 1;96(9):1200-6
16253582